GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Other Net Income (Loss)

Myriad Genetics (HAM:MYD) Other Net Income (Loss) : €0.0 Mil (TTM As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Other Net Income (Loss)?

Myriad Genetics's Other Net Income (Loss) for the three months ended in Mar. 2025 was €0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

Myriad Genetics's quarterly Other Net Income (Loss) stayed the same from Sep. 2024 (€0.0 Mil) to Dec. 2024 (€0.0 Mil) but then increased from Dec. 2024 (€0.0 Mil) to Mar. 2025 (€0.0 Mil).

Myriad Genetics Other Net Income (Loss) Historical Data

The historical data trend for Myriad Genetics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Other Net Income (Loss) Chart

Myriad Genetics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Myriad Genetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Myriad Genetics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Other Net Income (Loss)
Comparable Companies
CSTL FLGT CDNA PSNL STIM ATLN OPK NEOG LDDD ACRS TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT
Traded in Other Exchanges
MYGN:USA 0K3W:UK MYD:Germany
Address
322 North 2200 West, Salt Lake City, UT, USA, 84116
Website
https://www.myriad.com
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.